Episode Details

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses the safety of the prefusion RSV vaccine, if high or moderate dose of the quadrivalent influenza vaccine is better for protection against hospitalization, summarizes the new WHO COVID guidelines, revisits how to prevent pathogen transmission in healthcare setting, the under use of COVID oral antiviral and what occurs in persistently SARS-CoV-2 infected cells in culture after antiviral treatment, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how inflammatory markers change correlate with death when in ICU and if cognitive slowing is part of long COVID-19.

Become a patron of TWiV!

• Do you want a job in healthcare? (JAMA)
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Efficacy and safety of RSV vaccine after 2 seasons (CID)
• High vs moderate dose of quadrivalent influenza vaccine (CMI)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• WHO COVID guidance (WHO)
• Thoughts on COVID guidance (CIDRAP)
• Update on how to prevent pathogen transmission in healthcare settings (CDC)
• Underuse of antiviral drugs against COVID-19 (MMWR)
• Revisiting tissue culture cells persistently infected following antiviral therapy (bioRxiv)